FDA Grants InBios First Marketing Rights for Anthrax POC Test
InBios has been granted the U.S. Food and Drug Administration’s (FDA) first marketing rights for an anthrax point-of-care (POC) test.
InBios has been granted the U.S. Food and Drug Administration’s (FDA) first marketing rights for an anthrax point-of-care (POC) test.
The ViroKey SARS-CoV-2 RT-PCR Test v2.0 has the additional capability to be used for pooling, using a three-in-one media pooling strategy.
A new study on rapid COVID-19 testing is investigating whether a saliva-based rapid antigen testing is more effective than the more common PCR tests.
Intrivo has launched On/Go, an at-home, rapid COVID-19 antigen self-test designed to deliver results with 95% accuracy in just 10 minutes.
Read MoreCue Health Inc.and the NBA have announced that Cue will serve as the league’s Official Home and Point of Care COVID Test for the 2021-22 season.
Read MoreThe Biden Administration will buy $1 billion worth of rapid at-home PCR tests, aimed at increasing access to testing to drive down infections of SARS-CoV-2.
Read MoreARCpoint Labs is utilizing its national network of diagnostic testing facilities to help travelers find convenient locations for COVID-19 testing.
Read MoreAffinity Empowering is providing COVID testing as part of the Operation Expanded Testing to Georgia Fugees Academy Charter School.
Read MoreBD, a medical technology company, has been selected by the state of Washington to provide options for COVID-19 testing and screening in K-12 schools.
Read MoreThe Tech Guide from the September 2021 issue of Clinical Lab Products includes point-of-care assays and analyzers from 17 suppliers.
Read MoreLumiraDx announced the U.S. launch of its COVID-19 Surveillance Test, for environments such as schools and workplaces.
Read MoreCarolina Liquid Chemistries Corp. has launched MyPOCtest.com, an e-commerce website to help supply medical facilities with POC rapid tests.
Read MoreResearchers have confirmed the speed, accuracy, and simplicity of a novel, highly sensitive testing method for COVID-19.
Read MoreLumiraDx has announced receiving FDA EUA for its SARS-CoV-2 Ab test, which is used to help identify an adaptive immune response to SARS-CoV-2.
Read MoreNanoDx, Inc., has entered into a licensing agreement with IBM Research for use of its nanoscale sensors for accurate, rapid testing.
Read MoreTechnology developed by UCL and AHRI researchers could transform the ability to accurately interpret HIV test results.
Read MoreRoche has announced that the U.S. FDA has granted EUA for the cobas SARS-CoV-2 Nucleic acid test for use on the cobas Liat System.
Read MorePandemic preparedness requires long-term investments in disease surveillance, diagnostics, therapeutics, and vaccine research.
Read More